Welcome to our dedicated page for Embecta SEC filings (Ticker: EMBC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Embecta Corp. filings document a Nasdaq-listed medical device and medical supplies company with common stock trading under EMBC. Its regulatory disclosures cover operating and financial results, capital-structure information, material-event reports, and governance matters tied to its board, annual meeting and executive-compensation votes.
Recent 8-K reports furnish quarterly and annual results and disclose director changes, board leadership roles and stockholder voting outcomes. Proxy materials describe annual meeting proposals, director elections, auditor ratification, compensation votes, and business context for Embecta's insulin injection franchise, restructuring actions, discontinued patch pump program, and broader medical supplies strategy.
Embecta Corp. (EMBC) director Morris Milton Mayo reported selling 6,293 shares of Embecta common stock on September 4, 2026 in an open-market or private transaction at $5.875 per share. Following this sale, he directly holds 53,828.34 shares of Embecta common stock. No Rule 10b5-1 trading plan is reported for this transaction.
Embecta Corp. (EMBC) has a notice of proposed sale on Form 144 for common stock held for the account of director Morris Milton Mayo. The notice covers 6,293 shares of common stock to be sold through RBC Capital Markets LLC on NASDAQ, with an aggregate market value of $36,891.00 as stated in the filing.
Embecta reports 56,659,599 shares of common stock outstanding in connection with this notice; this is a baseline figure, not the amount being offered. The securities to be sold were acquired as directors compensation from the issuer on February 7, 2024.
Embecta Corp. is the subject of an updated Schedule 13G/A in which American Century Investment Management, Inc., American Century Companies, Inc. and the Stowers Institute for Medical Research report their current holdings of Embecta common stock (CUSIP 29082K105).
The reporting group discloses beneficial ownership of 154 shares of Embecta common stock, representing 0.0% of the class, with sole voting and sole dispositive power over these shares and no shared voting or dispositive power. They state they now own 5 percent or less of the class, and that various clients and investment accounts advised by American Century Investment Management have the right to receive dividends and sale proceeds from these securities. The filing also confirms the joint filing arrangement among the three reporting entities.
Embecta Corp. President and CEO Devdatt Kurdikar purchased 30,000 shares of common stock on August 12, 2026 at $4.6979 per share in an open-market or private transaction. Following this buy, his directly held stake increased to 804,918.728 shares of Embecta common stock.
Embecta Corp. SVP and CFO Jacob Elguicze purchased 20,000 shares of common stock on 2026-08-12 in an open-market or private transaction at $4.668 per share. Following this buy, his direct holdings increased to 309,138.604 shares of Embecta common stock.
Embecta Corp. officer Jeffrey Z. Mann, Pres, Pharm Svc&Prod Mgmt, CLO, reported an open-market purchase of 20,000 shares of common stock on 2026-08-12 at $4.99 per share. Following this transaction, his directly held position increased to 262,915.028 shares of Embecta common stock.
Embecta Corp. director Robert J. Hombach reported an open-market purchase of 45,000 shares of common stock on August 12, 2026 at a weighted-average price of $4.9744 per share. The shares were bought in multiple trades between $4.955 and $4.985 per share, bringing his direct holdings to 109,587.208 shares after the transaction. The filing indicates the transaction was not made pursuant to a Rule 10b5-1 trading plan.
Embecta Corp. executive Jean Casner, Chief Human Resources Officer, reported a code F transaction involving 1,480 shares of common stock on 2026-08-09. The shares were withheld to cover withholding taxes in connection with the vesting of restricted stock units. Following this tax-withholding disposition, Casner directly holds 85,914.87 shares of Embecta common stock, which include shares received as stock dividends.
Embecta Corp. reported weaker results for the quarter and nine months ended June 30, 2026. Quarterly revenue fell to $271.7 million, down 8.1% year over year, as lower pricing and volumes more than offset $13.8 million from the Owen Mumford acquisition and favorable currency. Gross margin declined to 56.4% from 66.7%, and net income dropped to $21.1 million or $0.36 diluted EPS, about half the prior-year level.
For the first nine months, revenue declined to $754.7 million and net income to $61.1 million, with margin pressure from higher cost of products sold. U.S. revenue decreased while international revenue grew modestly. Pen needles saw notable declines, partly offset by growth in safety and other products, including Owen Mumford.
The company closed the $208.0 million Owen Mumford acquisition, adding auto-injectors and other chronic-care devices, and recorded $24.4 million of goodwill. Embecta generated $90.1 million in operating cash flow, ended the quarter with $218.2 million in cash and restricted cash and $1,455.1 million of debt, repurchased 2.7 million shares for $8.7 million under a new $100.0 million authorization, and reduced its quarterly dividend from $0.15 to $0.01 per share. The company also disclosed a putative securities class action related to fiscal 2026 revenue guidance and stated it intends to defend the case vigorously.
Embecta Corp. reported third quarter fiscal 2026 revenue of $271.7 million, down 8.1% year-over-year, with U.S. revenue down 24.6% and International up 11.5%. Gross margin declined to 56.4% from 66.7%. Net income was $21.1 million (diluted EPS $0.36) versus $45.5 million ($0.78) a year earlier. Adjusted EBITDA was $85.7 million with a 31.5% margin, and adjusted EPS was $0.56, both below the prior-year quarter.
For the nine months ended June 30, 2026, revenue was $754.7 million, down 7.6%, with adjusted net income of $91.0 million and adjusted EPS of $1.53. The company completed the Owen Mumford acquisition, contributing $13.8 million of revenue year-to-date, and is expanding GLP‑1 co-packaging launches globally. Embecta ended the quarter with $218.2 million in cash and equivalents and restricted cash and $1.469 billion of debt principal outstanding, after borrowing $180 million and repaying about $53 million. It declared a quarterly dividend of $0.01 per share and reaffirmed fiscal 2026 revenue guidance of $1,015–$1,035 million while raising adjusted operating margin guidance to 23.50%–24.00% and adjusted EPS guidance to $1.80–$1.90.